Physician profile
Arthur Talansky
NPI 1477577963
$15,706.65
in general payments reported to CMS, 2019-2025
43 companies · $2,559 in 2025
The $2,559 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,283 · 2020: $1,396 · 2021: $1,610 · 2022: $2,448 · 2023: $2,152 · 2024: $2,258 · 2025: $2,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,910 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00 · Education: $18.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,910.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
| Education | $18.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,423.05 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,090.40 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $1,462.46 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,281.09 | 2019-2025 | Entyvio, Vpriv, Eohilia |
| Pfizer INC. | $1,132.01 | 2019-2025 | |
| Celgene Corporation | $763.27 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $587.77 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $576.85 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $362.46 | 2019-2024 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $359.68 | 2019-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $334.60 | 2019-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $316.76 | 2019-2024 | |
| Gilead Sciences, INC. | $282.08 | 2019-2024 | |
| Cumberland Pharmaceuticals, INC. | $216.31 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $205.23 | 2023-2025 | Vowst |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $204.12 | 2019 | |
| Redhill Biopharma INC. | $193.68 | 2020-2025 | Talicia |
| Genzyme Corporation | $176.04 | 2022-2025 | |
| Shire North American Group INC | $167.37 | 2019 | |
| Phathom Pharmaceuticals, INC. | $166.81 | 2024-2025 | Voquezna |
| Concordia Pharmaceuticals INC. | $145.08 | 2019 | |
| Intra-Sana Laboratories | $131.26 | 2022-2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| E.R. Squibb & Sons, L.L.C. | $122.19 | 2023 | Zeposia |
| Madrigal Pharmaceuticals | $108.93 | 2024-2025 | Resmetirom, Rezdiffra |
| Vivus LLC | $96.49 | 2019-2025 | Pancreaze |
| Daiichi Sankyo INC. | $90.13 | 2019-2022 | |
| Shionogi INC | $85.92 | 2019 | |
| Celltrion USA INC. | $78.20 | 2024-2025 | Vegzelma, Zymfentra |
| Ironwood Pharmaceuticals, INC | $77.58 | 2019-2023 | Linzess |
| Nestle Healthcare Nutrition INC. | $64.99 | 2021-2023 | |
| Conmed Corporation | $53.35 | 2025 | Conmed Biliary |
| Amgen INC. | $53.18 | 2023 | Amjevita, Avsola |
| Ipsen Biopharmaceuticals, INC | $46.70 | 2025 | Iqirvo, Bylvay |
| Endo Pharmaceuticals INC. | $40.67 | 2019 | |
| Ucb, INC. | $39.80 | 2019 | |
| Janssen Scientific Affairs, LLC | $35.77 | 2019 | |
| Capsovision, INC. | $34.14 | 2024 | Capsocam Plus |
| Medtronic, INC. | $25.77 | 2021-2024 | Gi Genius |
| Enterra Medical, INC. | $20.34 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $16.11 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.07 | 2023 | Dupixent |
| Qol Medical, LLC | $12.52 | 2019 | |
| Evoke Pharma, INC. | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Talansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.